ES2150447T3 - Formas purificadas de desoxiribonucleasa. - Google Patents

Formas purificadas de desoxiribonucleasa.

Info

Publication number
ES2150447T3
ES2150447T3 ES93914258T ES93914258T ES2150447T3 ES 2150447 T3 ES2150447 T3 ES 2150447T3 ES 93914258 T ES93914258 T ES 93914258T ES 93914258 T ES93914258 T ES 93914258T ES 2150447 T3 ES2150447 T3 ES 2150447T3
Authority
ES
Spain
Prior art keywords
components
deoxyribonuclease
species
application
purified forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93914258T
Other languages
English (en)
Inventor
John Frenz
Steven J Shire
Mary B Sliwkowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2150447T3 publication Critical patent/ES2150447T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION PROVEE LA IDENTIFICACION Y CARACTERIZACION DE DOS COMPONENTES DE UNA PREPARACION RECOMBINANTE DE DNASE. ESTOS COMPONENTES SON LAS DNASES HUMANA DESAMIDADA O NO DESAMIDADA PURIFICADA. SE INDICA TAMBIEN LA SEPARACION DE ESTOS COMPONENTES Y LA APLICACION DE LAS ESPECIES NO DESAMIDADAS COMO UN PRODUCTO FARMACEUTICO PER SE, Y EN PARTICULAR EN COMPOSICIONES EN DONDE LAS ESPECIES SON DESCRITAS DENTRO DE UNA VIA PLASTICA, PARA LA APLICACION EN ADMINISTRAR A PACIENTES QUE SUFREN DE AGOTAMIENTO PULMONAR.
ES93914258T 1992-06-08 1993-05-28 Formas purificadas de desoxiribonucleasa. Expired - Lifetime ES2150447T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/895,300 US5279823A (en) 1992-06-08 1992-06-08 Purified forms of DNASE

Publications (1)

Publication Number Publication Date
ES2150447T3 true ES2150447T3 (es) 2000-12-01

Family

ID=25404292

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93914258T Expired - Lifetime ES2150447T3 (es) 1992-06-08 1993-05-28 Formas purificadas de desoxiribonucleasa.

Country Status (30)

Country Link
US (4) US5279823A (es)
EP (2) EP0644932B1 (es)
JP (1) JP3383307B2 (es)
KR (2) KR100323357B1 (es)
AT (2) ATE455557T1 (es)
AU (1) AU682822B2 (es)
BG (1) BG62335B1 (es)
BR (1) BR9306670A (es)
CA (1) CA2137237C (es)
CZ (1) CZ293105B6 (es)
DE (3) DE69334317D1 (es)
DK (1) DK0644932T3 (es)
ES (1) ES2150447T3 (es)
FI (1) FI945549A7 (es)
GB (1) GB2282140B (es)
GE (1) GEP20002300B (es)
GR (1) GR3034718T3 (es)
HU (1) HU219549B (es)
IL (1) IL105724A (es)
MD (1) MD960288A (es)
NO (1) NO318644B1 (es)
NZ (1) NZ253559A (es)
PL (1) PL175873B1 (es)
PT (1) PT644932E (es)
RO (1) RO117188B1 (es)
RU (1) RU2238320C2 (es)
SK (1) SK282957B6 (es)
TJ (1) TJ396B (es)
UA (1) UA46693C2 (es)
WO (1) WO1993025670A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE176924T1 (de) * 1988-12-23 1999-03-15 Genentech Inc Verfahren zur herstellung von menschlicher dnase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
CA2184582C (en) 1994-03-04 2001-12-25 Hak-Kim Chan Pharmaceutically acceptable dnase formulation
DE69535787D1 (de) * 1994-03-04 2008-08-28 Genentech Inc Verbesserte dnase flüssige lösungen
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
EP0817839A1 (en) * 1994-05-05 1998-01-14 Human Genome Sciences, Inc. Human dnase
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
DE69522799T2 (de) * 1994-09-06 2002-06-20 Seiichi Tanuma Neuartige desoxyribonuklease
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
JP4118334B2 (ja) * 1996-02-05 2008-07-16 ジェネンテック・インコーポレーテッド ヒトｄｎアーゼ
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
PT1308456E (pt) * 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
ATE444771T1 (de) * 2000-02-11 2009-10-15 Respironics Respiratory Drug D Wirkstoffabgabevorrichtung
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
DK1285080T3 (da) * 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Fremgangsmåde til oprensning af alphavirusreplikonpartikler
MD20010375A (ro) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Malaxor
MD2260C2 (ro) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Malaxor
SI1543038T2 (sl) 2002-09-11 2020-12-31 Genentech, Inc. Čiščenje proteinov
US7067298B2 (en) 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7595179B2 (en) 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
US20080160577A1 (en) * 2005-02-04 2008-07-03 Glaxo Group Limited Optimization of Heterologous Polypeptide Expression
KR100655438B1 (ko) * 2005-08-25 2006-12-08 삼성전자주식회사 자기 기억 소자 및 그 형성 방법
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
PT2086642E (pt) * 2006-10-18 2014-09-30 Periness Ltd Dnase para o tratamento de subfertilidade masculina
CN101889025B (zh) 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
WO2009123950A2 (en) * 2008-03-31 2009-10-08 The Trustees Of The University Of Pennsylvania Chimera comprising bacterial cytotoxin and methods of using the same
EP3318635A1 (en) 2011-04-21 2018-05-09 University of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
US10370408B2 (en) * 2014-06-25 2019-08-06 Jhl Biotech, Inc. Method for purification of a DNase or RNase protein from a sample
EP3214172B1 (en) 2014-10-31 2019-02-13 JCR Pharmaceuticals CO., LTD. Method for producing remcombinant human dnasei
WO2017019876A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
US11060088B2 (en) 2016-02-12 2021-07-13 University Of Massachusetts Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11401507B2 (en) 2016-11-17 2022-08-02 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
WO2021244964A1 (en) 2020-06-01 2021-12-09 Black Cat Bio Limited Compositions and methods for treating infections and netopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Canada Packers Limited Isolation and purification of deoxyribonuclease
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
ATE176924T1 (de) * 1988-12-23 1999-03-15 Genentech Inc Verfahren zur herstellung von menschlicher dnase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Also Published As

Publication number Publication date
JP3383307B2 (ja) 2003-03-04
DE69329200T2 (de) 2001-04-26
BG62335B1 (bg) 1999-08-31
WO1993025670A1 (en) 1993-12-23
EP1013284B1 (en) 2010-01-20
US5279823A (en) 1994-01-18
EP1013284A2 (en) 2000-06-28
FI945549L (fi) 1994-11-25
GEP20002300B (en) 2000-11-25
NO944752L (no) 1994-12-08
AU4398193A (en) 1994-01-04
DK0644932T3 (da) 2001-01-02
CZ303294A3 (en) 1995-06-14
US6440412B1 (en) 2002-08-27
GR3034718T3 (en) 2001-01-31
US20030077267A1 (en) 2003-04-24
NZ253559A (en) 1996-11-26
US6932965B2 (en) 2005-08-23
RU2238320C2 (ru) 2004-10-20
FI945549A0 (fi) 1994-11-25
DE69334317D1 (de) 2010-03-11
EP1013284A3 (en) 2000-08-30
BG99234A (bg) 1995-07-28
MD960288A (ro) 1998-01-31
SK282957B6 (sk) 2003-01-09
BR9306670A (pt) 1998-12-08
CZ293105B6 (cs) 2004-02-18
US5783433A (en) 1998-07-21
RU94046424A (ru) 1997-03-10
RO117188B1 (ro) 2001-11-30
KR100323357B1 (ko) 2002-02-19
ATE195340T1 (de) 2000-08-15
HU9403512D0 (en) 1995-02-28
KR100302092B1 (ko) 2001-10-22
DE4392749T1 (de) 1995-07-20
JPH07507455A (ja) 1995-08-24
UA46693C2 (uk) 2002-06-17
NO318644B1 (no) 2005-04-25
TJ396B (en) 2004-12-29
EP0644932A1 (en) 1995-03-29
SK149594A3 (en) 1996-01-10
HU219549B (hu) 2001-05-28
CA2137237A1 (en) 1993-12-23
EP0644932B1 (en) 2000-08-09
IL105724A0 (en) 1993-09-22
IL105724A (en) 1997-06-10
ATE455557T1 (de) 2010-02-15
AU682822B2 (en) 1997-10-23
DE69329200D1 (de) 2000-09-14
PT644932E (pt) 2001-02-28
CA2137237C (en) 2004-10-26
PL175873B1 (pl) 1999-02-26
GB2282140B (en) 1996-04-17
GB2282140A (en) 1995-03-29
NO944752D0 (no) 1994-12-08
FI945549A7 (fi) 1994-11-25
HUT70468A (en) 1995-10-30
GB9423695D0 (en) 1995-01-11

Similar Documents

Publication Publication Date Title
ES2150447T3 (es) Formas purificadas de desoxiribonucleasa.
MX9308016A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
ATE213164T1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
NO20002788D0 (no) Nye forbindelser
YU59092A (sh) Formulacije aerosola koji ne sadrže hlorofluorougljenična jedinjenja
ES2054038T3 (es) Esteres y tioesteres aromaticos, su procedimiento de preparacion y su utilizacion en medicina humana o veterinaria y en cosmetica.
BR8707672A (pt) Pirazolinas inseticidas
EE04021B1 (et) 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
ES2079589T3 (es) Agentes farmaceuticos.
PT749317E (pt) Aplicacoes terapeuticas de produtos dimericos de proteinas bactericidas indutoras da permeabilidade
AR019853A1 (es) Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci
FI946073A0 (fi) Vitamiini D-sarjan, 20-asemassa modifioituja johdannaisia, menetelmä tällaisten johdannaisten valmistamiseksi, menetelmässä käytettäviä välituotteita, mainittuja johdannaisia sisältäviä farmaseuttisia valmisteita ja johdannaisten käyttö lääkeaineiden valmistamiseen
FI951298A0 (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
MX9308005A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
PT98371A (pt) Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
RU95106680A (ru) Бициклические ароматические соединения и содержащие их фармацевтические и косметические композиции
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
MX9308010A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
PT95697A (pt) Processo para a preparacao de composicoes farmaceuticas contendo substancias antiandrogenicamente activas
TR200100637T2 (tr) Yeni doğal ürün türevleri
ATE226065T1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
IT1284873B1 (it) Derivati stabili di ubichinolo procedimenti per la loro produzione e loro impiego farmaceutico
ATE277625T1 (de) Pharmazeutische zusammensetzung aus spinnengiften sowie deren herstellung und verwendung zur behandlung von tumorerkrankungen
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 644932

Country of ref document: ES